Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt

doi:10.3748/wjg.v27.i30.5088

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 30

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6740)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

414

WORD

218

HTML

2645

Figures (1-4)

239

Tables (1-2)

214

Sum=3730

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

429

Download

941

Sum=1370

Publishing Process of This Article

Item

Count

Browse

517

Download

1123

Sum=1640

Aug 14, 2021 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Aug 14, 2021; 27(30): 5088-5099
Published online Aug 14, 2021. doi: 10.3748/wjg.v27.i30.5088

Full Size Figure Download Figure

Figure 1 Overall survival, hepatic encephalopathy free survival, and hepatocellular carcinoma free survival rate in tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, and entecavir groups. A: Survival; B: Freedom from hepatic encephalopathy; C: Freedom from hepatocellular carcinoma. HCC: Hepatocellular carcinoma; HE: Hepatic encephalopathy; TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.

Citation: Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099
URL: https://www.wjgnet.com/1007-9327/full/v27/i30/5088.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i30.5088